·	Application No.	Applicant(s)
Notice of Allowability	10/749 055	MOTODA ET AL.
	10/748,055 Examiner	Art Unit
		1000
	James S. Ketter	1636
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. A This communication is responsive to the authorization on 25 April 2006 by Mark J: Nuell of the Examiner's Amendment.		
2.  The allowed claim(s) is/are 17-31.		
<ul> <li>3.</li></ul>		
1. 🖂 Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
		*
		•
Attachment(s)		
1. Notice of References Cited (PTO-892)		atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	
3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 11/14/05	Paper No./Mail Dat 18), 7. ⊠ Examiner's Amendn	e nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit	8.   Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.	
		•

Application/Control Number: 10/748,055

Art Unit: 1636

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mark J. Nuell on 25 April 2006. The format of the amendment below recreates the intended amendment filed 8 February 2006.

The application has been amended as follows:

In the claims:

Claims 14, 15, 32 and 33 have been cancelled.

- 24. (currently amended) The method of any one of claims 15-17 claim 17, wherein the second DNA fragment and/or the third DNA fragment are single-stranded DNA.
- 25. (currently amended) The method of any one of claims 15-17 claim 17, wherein the third DNA fragment comprises a transcription termination sequence.
- 26. (currently amended) The method of any one of claims 15-17 claim 17, wherein at least one of the second DNA fragment and the third DNA fragment comprises a sequence encoding a tag peptide.

Application/Control Number: 10/748,055

Art Unit: 1636

27. (currently amended) The method of any one of claims 14-17 claim 17, in which the desired nucleotide sequence of the second sense primer comprises a sequence encoding a tag peptide.

Any inquiry concerning this communication or earlier communications from the Examiner with respect to the examination on the merits should be directed to James Ketter whose telephone number is (571) 272-0770. The Examiner normally can be reached on M-F (9:00-6:30), with alternate Fridays off.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Remy Yucel, can be reached at (571) 272-0781.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of

Application/Control Number: 10/748,055

Art Unit: 1636

the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Jsk May 9, 2006

> JAMES KETTER PRIMARY EXAMINER